Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 10 PH6 versus AMINOSYN RF 5 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 10 PH6 versus AMINOSYN RF 5 2.
AMINOSYN 10% (PH6) vs AMINOSYN-RF 5.2%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 10% is a parenteral amino acid solution that provides essential and non-essential amino acids for protein synthesis, helping to maintain nitrogen balance and support tissue repair and growth in patients unable to receive adequate nutrition enterally.
Aminosyn-RF 5.2% is an amino acid solution that provides essential and nonessential amino acids for protein synthesis, primarily in patients with renal impairment. It is designed to reduce ureagenesis and nitrogenous waste accumulation by supplying a higher proportion of essential amino acids while limiting total nitrogen load.
Intravenous infusion: 1 to 1.5 g/kg/day (equivalent to 10 to 15 mL/kg/day of 10% solution) for adult patients with normal nutritional status; adjust based on metabolic needs.
1-1.5 g/kg/day intravenously as a continuous infusion, typically 500 mL to 1000 mL/day depending on amino acid requirements and fluid status. Dose is expressed as grams of amino acids per kg of ideal body weight per day.
None Documented
None Documented
The terminal elimination half-life of individual amino acids varies (1–4 hours) depending on metabolic demand and renal function. For the amino acid mixture, the effective half-life is approximately 2 hours in patients with normal renal function. This short half-life necessitates continuous or frequent infusion to maintain stable plasma levels.
The terminal elimination half-life of infused amino acids is approximately 10–20 minutes, reflecting rapid distribution and metabolism; clinical context: continuous infusion maintains steady state within 30 minutes.
Amino acids from Aminosyn 10% are primarily utilized for protein synthesis and metabolic processes. Excess nitrogen is eliminated via the kidneys as urea (renal elimination accounts for >90% of nitrogen excretion). Minimal biliary/fecal elimination (<5%) occurs via unabsorbed amino acids in patients with malabsorption. In renal impairment, elimination is reduced.
Primarily renal; >95% of infused essential amino acids and small peptides are reabsorbed; excess amino acids are deaminated and nitrogen excreted as urea in urine (renal clearance of urea). Biliary/fecal excretion is negligible (<2%).
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution